Consolidated Statements of Cash Flows (USD $) In Millions, unless otherwise specified	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 1,233.2	$ 601.1
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	307.1	229.4
Share based compensation	78.3	55.2
Change in fair value of contingent consideration	26.3	28.4
Impairment of intangible assets	188.0	19.9
Goodwill impairment charge	0	7.1
Write down of assets	14.0	8.3
Gain on sale of product rights	(86.2)	(14.6)
Unwind of Viropharma inventory fair value step-up	90.6	0
Other, net	16.5	(3.9)
Movement in deferred taxes	63.1	16.1
Equity in earnings of equity method investees	(3.8)	(0.6)
Changes in operating assets and liabilities:
Increase in accounts receivable	(92.1)	(215.2)
Increase in sales deduction accruals	28.2	108.7
Increase in inventory	(15.8)	(39.9)
Increase in prepayments and other assets	(114.7)	(70.9)
Decrease in accounts and notes payable and other liabilities	(92.8)	(71.4)
Returns on investment from joint venture	0	3.2
Net cash provided by operating activities	1,673.5	852.7
CASH FLOWS FROM INVESTING ACTIVITIES:
Movements in restricted cash	(32.3)	0.5
Purchases of subsidiary undertakings and businesses, net of cash acquired	(4,104.4)	(227.8)
Purchases of non-current investments	(22.8)	(9.9)
Purchases of property, plant and equipment ("PP&E")	(49.8)	(110.3)
Proceeds from short-term investments	57.8	0
Proceeds from disposal of non-current investments	21.3	8.6
Proceeds received on sale of product rights	122.7	15.0
Other, net	1.3	2.9
Net cash used in investing activities	(4,006.2)	(321.0)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long-term and short-term borrowings	2,310.8	0
Repayment of revolving line of credit	(1,461.8)	0
Repayment of debt acquired through business combinations	(551.5)	0
Proceeds from ViroPharma call options	346.7	0
Payment of dividend	(99.6)	(79.2)
Excess tax benefit associated with exercise of stock options	37.4	9.5
Contingent consideration payments	(12.8)	(11.3)
Payments to acquire shares (in USD)	0	(240.8)
Other, net	(2.0)	(5.5)
Net cash provided by/(used in) financing activities	567.2	(327.3)
Effect of foreign exchange rate changes on cash and cash equivalents	(6.2)	(0.5)
Net (decrease)/increase in cash and cash equivalents	(1,771.7)	203.9
Cash and cash equivalents at beginning of period	2,239.4	1,482.2
Cash and cash equivalents at end of period	467.7	1,686.1
Supplemental information associated with continuing operations:
Net Interest received/(paid)	8.0	(17.6)
Net Income taxes received/(paid)	76.3	(244.7)
Continung operations
Adjustments to reconcile net income to net cash provided by operating activities:
Goodwill impairment charge		7.1
Gain on sale of product rights	(86.2)
Discontinued operations
Adjustments to reconcile net income to net cash provided by operating activities:
Goodwill impairment charge		191.8
Gain on sale of product rights	33.6
Goowill impairment charge total
Adjustments to reconcile net income to net cash provided by operating activities:
Goodwill impairment charge		198.9
Total
Adjustments to reconcile net income to net cash provided by operating activities:
Gain on sale of product rights	(52.6)
EBT
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments to acquire shares (in USD)	0	(50.3)
Share Buy-back Program
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments to acquire shares (in USD)	$ 0	$ (190.5)